2 Dividend Stocks to Buy Hand Over Fist in April

Core Viewpoint - The healthcare sector is often avoided by investors due to a lack of reliable dividend payers, but notable exceptions exist in companies like Amgen and AbbVie, which have attractive dividend policies [1][2]. Group 1: Amgen - Amgen is recognized for its strong performance in the obesity drug market and has a robust lineup of blockbuster drugs and a promising pipeline [3]. - In the previous year, Amgen's overall revenue increased by 19% to over $33.4 billion, with net income at nearly $4.1 billion, despite higher costs in research and development [5]. - Amgen raised its quarterly dividend by 6% to $2.38 per share, resulting in a yield of approximately 3%, which is nearly double the average yield of S&P 500 companies [6]. Group 2: AbbVie - AbbVie emphasizes its quarterly dividend, currently yielding over 3%, and has a history of regular dividend increases, with a recent 6% hike to $1.64 per share [8]. - Over the past decade, AbbVie has more than tripled its per-share payout, demonstrating a strong commitment to returning value to shareholders [9]. - AbbVie reported a nearly 4% increase in total net revenue to $56.3 billion, with net income slightly down to just under $4.3 billion due to rising costs [11]. - The company is well-positioned for future growth, with a projected compound annual growth rate (CAGR) in revenue in the high single-digit percentages through 2029, and an increased sales forecast for its drugs Rinvoq and Skyrizi to $31 billion by 2027 [12].